Clinical prognostic value of DNA methylation in hepatoblastoma: Four novel tumor suppressor candidates

Cancer Science

Volumn 107, Issue 6, 2016, Pages 812-819

  Honda, Shohei ^a   Minato, Masashi ^a   Suzuki, Hiromu ^b   Fujiyoshi, Masato ^a   Miyagi, Hisayuki ^a   Haruta, Masayuki ^c   Kaneko, Yasuhiko ^c   Hatanaka, Kanako C ^d   Hiyama, Eiso ^e   Kamijo, Takehiko ^c   Okada, Tadao ^f   Taketomi, Akinobu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^e Japanese Study Group for Pediatric Liver Tumor (JPLT)   (Japan)

^f HOKKAIDO UNIVERSITY OF EDUCATION   (Japan)

Author keywords

Hepatoblastoma; methylation; prognostic marker; survival; tumor suppressor

Indexed keywords

DNA;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; DNA METHYLATION; EMBRYO; EVENT FREE SURVIVAL; FEMALE; FETUS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOME-WIDE ASSOCIATION STUDY; GPR180 GENE; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MST1R GENE; MULTIVARIATE ANALYSIS; OCIAD2 GENE; PARP6 GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; PYROSEQUENCING; SURVIVAL RATE; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

EID: 84979052714     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12928     Document Type: Article

References (32)

1. von Schweinitz D. Hepatoblastoma: recent developments in research and treatment. Semin Pediatr Surg 2012; 21: 21–30.
2. Ueda Y, Hiyama E, Kamimatsuse A, Kamei N, Ogura K, Sueda T. Wnt signaling and telomerase activation of hepatoblastoma: correlation with chemosensitivity and surgical resectability. J Pediatr Surg 2011; 46: 2221–7.
3. Yamada S, Ohira M, Horie H et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004; 23: 5901–11.
4. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of theβ–catenin gene. Cancer Res 1999; 59: 269–73.
5. Ohnishi H, Kawamura M, Hanada R et al. Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas. Genes Chromosom Cancer 1996; 15: 187–90.
6. Taniguchi K, Roberts LR, Aderca IN et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002; 21: 4863–71.
7. Honda S, Haruta M, Sugawara W et al. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer 2008; 123: 1117–25.
8. Honda S, Miyagi H, Suzuki H et al. RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients. Pediatr Surg Int 2013; 29: 1147–52.
9. Honda S, Arai Y, Haruta M et al. Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma. Br J Cancer 2008; 99: 1891–9.
10. Rumbajan JM, Maeda T, Souzaki R et al. Comprehensive analyses of imprinted differentially methylated regions reveal epigenetic and genetic characteristics in hepatoblastoma. BMC Cancer 2013; 13: 608.
11. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet 2010; 11: 191–203.
12. Toyota M, Suzuki H, Yamashita T et al. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci 2009; 100: 787–91.
13. Hishiki T, Matsunaga T, Sasaki F et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int 2011; 27: 1–8.
14. Hiyama E, Ueda Y, Onitake Y et al. Japanese Study Group for Pediatric Liver Tumor. A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT). Pediatr Surg Int 2013; 29: 1071–5.
15. Brown J, Perilongo G, Shafford E et al. Pretreatment prognostic factors for children with hepatoblastoma- results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 2000; 36: 1418–25.
16. Nojima M, Maruyama R, Yasui H et al. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res 2009; 15: e4356–64.
17. Strausberg RL, Feingold EA, Grouse LH et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA 2002; 99: 16899–903.
18. Ishiyama T, Kano J, Anami Y et al. OCIA domain containing 2 is highly expressed in adenocarcinoma mixed subtype with bronchioloalveolar carcinoma component and is associated with better prognosis. Cancer Sci 2007; 98: 50–7.
19. Tuncel H, Tanaka S, Oka S et al. PARP6, a mono(ADP-ribosyl) transferase and a negative regulator of cell proliferation, is involved in colorectal cancer development. Int J Oncol 2012; 41: 2079–86.
20. Wha Koh Y, Park C, Hyun Yoon D, Suh C, Huh J. MET and MST1R as prognostic factors for classical Hodgkin's lymphoma. Mod Pathol 2013; 26: 1172–82.
21. Yao HP, Zhou YQ, Zhang R, Wang MH. MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer 2013; 13: 466–81.
22. Welm AL, Sneddon JB, Taylor C et al. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA 2007; 104: 7570–5.
23. Angeloni D, Danilkovitch-Miagkova A, Ivanova T, Braga E, Zabarovsky E, Lerman MI. Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter. Oncogene 2007; 26: 4499–512.
24. Iida A, Tanaka T, Nakamura Y. High-density SNP map of human ITR, a gene associated with vascular remodeling. J Hum Genet 2003; 48: 170–2.
25. Camps J, Pitt JJ, Emons G et al. Genetic amplification of the NOTCH modulator LNX2 upregulates the WNT/β-catenin pathway in colorectal cancer. Cancer Res 2013; 73: 2003–13.
26. Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development indigestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012; 143: 550–63.
27. Abe M, Ohira M, Kaneda A et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005; 65: 828–34.
28. Borssén M, Palmqvist L, Karrman K et al. Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia. PLoS ONE 2013; 8: e65373.
29. Mack SC, Witt H, Piro RM et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 2014; 506: 445–50.
30. Asada K, Abe M, Ushijima T. Clinical application of the CpG island methylator phenotype to prognostic diagnosis in neuroblastomas. J Hum Genet 2013; 58: 428–33.
31. Cairo S, Armengol C, De Reyniès A et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14: 471–84.
32. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005; 5: 223–31.